Open-Ended, Dicer-Cleavable Periodic shRNA Generated by Rolling Circle Transcription

Technology #18076

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Extended knockdown of GFP by csiRNA (csi25), T1-cleaved csiRNA (T1-csi25), and siRNA (si) with Mirus TranslT-X2® in GFP-expressing HeLa cells, at an effective siRNA concentration of 5 nM.Luciferase knockdown by luciferase-targeting and scrambled (scr) csiRNA (csi25), T1-cleaved csiRNA (T1-csi25), and siRNA with Mirus TranslT-X2® in luciferase-expressing (a) SKOV3 cells and (b) UCI1O1 cells, with normalization of measured luciferase expression to total protein.
Categories
Inventors
Professor Paula Hammond
Department of Chemical Engineering, MIT
External Link (hammondlab.mit.edu)
Kevin Shopsowitz
Koch Institute for Integrative Cancer Research, MIT
Connie Wu
Department of Chemical Engineering, MIT
Managed By
Jon Gilbert
MIT Technology Licensing Officer
Patent Protection

Concatemeric RNA Molecules, Compositions, and Methods and Uses Thereof

PCT Patent Application Filed
Publications
Engineering Periodic shRNA for Enhanced Silencing Efficacy.
Molecular Therapy , 2016

Applications

This invention reduces dosages and improves efficacy of RNA interference drugs including cancer therapeutics.

Problem Addressed

Short interfering RNAs (siRNAs) have great therapeutic potential but clinical translation has been hindered by poor in vivo stability, low loading efficiency, and dose-limiting toxicity. The generation of periodic short hairpin RNA (concatemeric siRNA) via rolling circle transcription (RCT) of a dumbbell shaped DNA template, which may be processed by Dicer proteins into siRNAs, has been reported as an alternative source of RNA interference. However, due to a lack of open ends, Dicer cleavage of periodic short hairpin RNA (p-shRNA) is inefficient. This invention is a more stable, cleavable p-shRNA containing open ends for efficient Dicer processing enabling high silencing efficacy with smaller amounts of delivery materials.

Technology

This designed p-shRNA before cleavage is generated from a dumbbell DNA template consisting of a 21 to 29 base pair region encoding a siRNA sequence, with one single stranded loop containing one or more guanosine residues, and the other loop containing no guanosine residues. The p-shRNA is then treated with RNase T1 which specifically cleaves single stranded RNA at the 3’ ends of guanosine residues, to produce siRNA repeats connected by single stranded linkers at one end, with the other end accessible for efficient Dicer cleavage. The inventors have shown that this Dicer-cleavable p-shRNA demonstrates much greater silencing activity than unmodified p-shRNA in GFP-expressing HeLa cells, as well as significant reporter gene knockdown in SKOV3 and UCI101 ovarian cancer cells. This p-shRNA’s greater molecular weight and flexibility compared to siRNA can potentially allow more stable complexation using less delivery materials making it ideal for optimizing gene delivery vehicles.

Advantages

  • Improves efficacy of RNA inference drugs while allowing for reduced dosage amounts and frequencies